Valerio Therapeutics enters exclusive R&D collaboration with Abivax, secures up to €2.4 million upfront

Valerio Therapeutics has entered a binding term sheet for an exclusive global R&D collaboration with Abivax focused on immune-mediated inflammatory diseases. Valerio will receive up to €2.4 million upfront, plus potential development milestones and royalties. The partnership covers candidate identification through preclinical testing, with Abivax holding options for further development. This non-dilutive funding supports Valerio's precision RNA pipeline, though definitive agreements are pending.

Valerio Therapeutics entered a binding term sheet with Abivax for an exclusive global R&D collaboration in immune-mediated inflammatory diseases. * Valerio to receive upfront payment up to EUR 2.4 million; eligible for development and commercial milestones plus royalties on net sales. * Collaboration covers identification, design, manufacturing, preclinical testing of candidates; Abivax may take selected programs into further development. * Definitive co-ownership and license agreement still pending; transaction positioned as non-dilutive funding for Valerio’s precision RNA pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Valerio Therapeutics entered a binding term sheet with Abivax for an exclusive global R&D collaboration in immune-mediated inflammatory diseases. * Valerio to receive upfront payment up to EUR 2.4 million; eligible for development and commercial milestones plus royalties on net sales. * Collaboration covers identification, design, manufacturing, preclinical testing of candidates; Abivax may take selected programs into further development. * Definitive co-ownership and license agreement still pending; transaction positioned as non-dilutive funding for Valerio’s precision RNA pipeline. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valerio Therapeutics SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here